GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Net Cash per Share

Champions Oncology (Champions Oncology) Net Cash per Share : $-1.79 (As of Jan. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Champions Oncology's Net Cash per Share for the quarter that ended in Jan. 2024 was $-1.79.

The historical rank and industry rank for Champions Oncology's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Champions Oncology was 273.00. The lowest was 11.81. And the median was 43.13.

CSBR's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4.165
* Ranked among companies with meaningful Price-to-Net-Cash only.

Champions Oncology Net Cash per Share Historical Data

The historical data trend for Champions Oncology's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Net Cash per Share Chart

Champions Oncology Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.50 -0.57 -1.15 -1.28 -1.44

Champions Oncology Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.29 -1.44 -1.72 -1.67 -1.79

Competitive Comparison of Champions Oncology's Net Cash per Share

For the Biotechnology subindustry, Champions Oncology's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Price-to-Net-Cash falls into.



Champions Oncology Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Champions Oncology's Net Cash per Share for the fiscal year that ended in Apr. 2023 is calculated as

Net Cash per Share (A: Apr. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(10.118-29.675-0)/13.5442
=-1.44

Champions Oncology's Net Cash per Share for the quarter that ended in Jan. 2024 is calculated as

Net Cash per Share (Q: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(4.468-28.845-0)/13.5938
=-1.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Champions Oncology  (NAS:CSBR) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Champions Oncology Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology (Champions Oncology) Business Description

Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093